PRIVACY POLICY

Last Updated: September 13th, 2022

This Privacy Policy (“Policy”) describes the manner in which Galvanize Therapeutics, Inc. (“Galvanize”, “we,” or “us”) and our website at www.Galvanizetx.com (the “Site”) use and collect data from individuals. This Policy, which is incorporated into and is subject to the Galvanize Therapeutics Website Terms of Use www.Galvanizetx.com describes the information that we gather from you on the Site, how we use and disclose such information, and the steps we take to protect such information.

INFORMATION WE COLLECT ON THIS SITE

  • User-provided Information. When you use the Site, we may collect information about you, including your name, email address, mailing address, or preferences and we may link this information with other information about you. You may provide us with information in various ways on the Site. For example, you provide us with information when you send us communications through the “Contact Us” feature on the Site.
  • Cookies and Automatically Collected Information. When you use the Site, we may send one or more cookies – small text files containing a string of alphanumeric characters – to your device. We may use both session cookies and persistent cookies. A session cookie disappears after you close your browser. A persistent cookie remains after you close your browser and may be used by your browser on subsequent visits to the Site. Please review your web browser “Help” file to learn the proper way to modify your cookie settings. Please note that if you delete, or choose not to accept, cookies from the Site, you may not be able to utilize the features of the Site to their fullest potential. We may use third party cookies on our Site as well. For instance, we use Google Analytics to collect and process certain analytics data. Google provides some additional privacy options described at www.google.com/policies/privacy/partners/ regarding Google Analytics cookies. Galvanize does not process or respond to web browsers’ “do not track” signals or other similar transmissions that indicate a request to disable online tracking of users who visit our Site or who use our Site.

We may also automatically record certain information from your device by using various types of technology, including “clear gifs” or “web beacons.” This automatically collected information may include your IP address or other device address or ID, web browser and/or device type, the web pages or sites that you visit just before or just after you use the Site, the pages or other content you view or otherwise interact with on the Site, and the dates and times that you visit, access, or use the Site. We also may use these technologies to collect information regarding your interaction with email messages, such as whether you opened, clicked on, or forwarded a message. This information is gathered from all users, and may be connected with other information about you.

  • Third Party Web Beacons and Third Party Buttons. We may display third-party content on the Site, including third-party advertising. Third-party content may use cookies, web beacons, or other mechanisms for obtaining data in connection with your viewing of the third party content on the Site. Additionally, we may implement third party buttons (such as Facebook “like” or “share” buttons) that may function as web beacons even when you do not interact with the button. Information collected through third-party web beacons and buttons is collected directly by these third parties, not by Galvanize. Information collected by a third party in this manner is subject to that third party’s own data collection, use, and disclosure policies.
  • Information from Other Sources. We may obtain information from third parties and sources other than the Site, such as our partners and advertisers.

HOW WE USE THE INFORMATION WE COLLECT

We use information we collect on the Site in a variety of ways in providing the Site and operating our business, including the following:

  • We use the information that we collect on the Site to operate, maintain, enhance and provide all features of the Site, to provide services and information that you request, to respond to comments and questions and otherwise to provide support to users.
  • We use the information that we collect on the Site to understand and analyze the usage trends and preferences of our users, to improve the Site, and to develop new products, services, features, and functionality.
  • We may use your email address or other information we collect to contact you for administrative purposes such as customer service or to send communications, including updates on promotions and events, relating to products and services offered by us.
  • We may use cookies and automatically collected information to: (i) personalize our Site, such as remembering information about you so that you will not have to re-enter it during your visit or the next time you visit the Site; (ii) monitor and analyze the effectiveness of the Site; and (iii) monitor aggregate site usage metrics such as total number of visitors and pages viewed.

WHEN WE DISCLOSE INFORMATION

Except as described in this Policy, we will not disclose information about you that we collect on the Site to third parties without your consent. We may disclose information to third parties if you consent to us doing so, as well as in the following circumstances:

  • We work with third party service providers to provide website, application development, hosting, maintenance, and other services for us. These third parties may have access to or process information about you as part of providing those services for us. Generally, we limit the information provided to these service providers to that which is reasonably necessary for them to perform their functions, and we require them to agree to maintain the confidentiality of such information.
  • We may disclose information about you if required to do so by law or in the good-faith belief that such action is necessary to comply with state and federal laws, in response to a court order, judicial or other government subpoena or warrant, or to otherwise cooperate with law enforcement or other governmental agencies.
  • We also reserve the right to disclose information about you that we believe, in good faith, is appropriate or necessary to: (i) take precautions against liability; (ii) protect ourselves or others from fraudulent, abusive, or unlawful uses or activity; (iii) investigate and defend ourselves against any third-party claims or allegations; (iv) protect the security or integrity of the Site and any facilities or equipment used to make the Site available; or (v) protect our property or other legal rights (including, but not limited to, enforcement of our agreements), or the rights, property, or safety of others.
  • Information about our users may be disclosed and otherwise transferred to an acquirer, successor, or assignee as part of any merger, acquisition, debt financing, sale of assets, or similar transaction, or in the event of an insolvency, bankruptcy, or receivership in which information is transferred to one or more third parties as one of our business assets.
  • We may make certain aggregated, automatically-collected, or otherwise non-personal information available to third parties for various purposes, including: (i) compliance with various reporting obligations; or (ii) for business or marketing purposes.

Your choices

You may, of course, decline to share certain information with us, in which case we may not be able to provide to you some of the features and functionality of the Site. You may update, correct, or delete your account information and preferences at any time by contacting us. Please note that while any changes you make will be reflected in active user databases within a reasonable period of time, we may retain all information you submit for backups, archiving, prevention of fraud and abuse, analytics, satisfaction of legal obligations, or where we otherwise reasonably believe that we have a legitimate reason to do so. If you receive commercial email from us, you may unsubscribe at any time by following the instructions contained within the email.

Third-party sites

The Site may contain features or links to websites and services provided by third parties. Any information you provide on third-party sites or services is provided directly to the operators of such services and is subject to those operators’ policies, if any, governing privacy and security, even if accessed through the Site. We are not responsible for the content or privacy and security practices and policies of third-party sites or services to which links or access are provided through the Site. We encourage you to learn about third parties’ privacy and security policies before providing them with information.

Children’s privacy

Protecting the privacy of young children is especially important. Our Site is not directed to children under the age of 13, and we do not knowingly collect personal information from children under the age of 13 without obtaining parental consent.

Data security

We use certain physical, managerial, and technical safeguards that are designed to improve the integrity and security of information that we collect and maintain. Please be aware that no security measures are perfect or impenetrable. We cannot and do not guarantee that information about you will not be accessed, viewed, disclosed, altered, or destroyed by breach of any of our physical, technical, or managerial safeguards.

International visitors

The Site is hosted in the United States and is intended for visitors located within the United States. If you choose to use the Site from the European Union or other regions of the world with laws governing data collection and use that may differ from U.S. law, then please note that you are transferring your personal information outside of those regions to the United States for storage and processing. Also, we may transfer your data from the U.S. to other countries or regions in connection with storage and processing of data, fulfilling your requests, and operating the Site. By providing any information, including personal information, on or to the Site, you consent to such transfer, storage, and processing.

Changes and updates to this policy

Please revisit this page periodically to stay aware of any changes to this Policy, which we may update from time to time. If we modify this Policy, we will make it available through the Site, and indicate the date of the latest revision. In the event that the modifications materially alter your rights or obligations hereunder, we will make reasonable efforts to notify you of the change. For example, we may generate a pop-up or similar notification when you access the Site for the first time after such material changes are made. Your continued use of the Site after the revised Policy has become effective indicates that you have read, understood and agreed to the current version of this Policy.

How to contact us

Please contact us with any questions or comments about this Policy, information we have collected or otherwise obtained about you, our use and disclosure practices, or your consent choices by email at info@galvanizetx.com.

Galvanize Therapeutics, Inc.
3200 Bridge Parkway
Redwood City, CA 94065

Laura Francis

CEO and Board Member of SI-BONE, Inc.

Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley based high-growth medical device company. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Laura played a pivotal role in bringing the company public in October 2018 and building the operations of the business. Prior to joining SI-BONE, Laura held other executive and leadership roles with public and private life science companies, including Auxogyn, now part of Progyny (Nasdaq: PGNY), Promega Corporation, and Bruker Corporation (Nasdaq: BRKR). Earlier in her career, she was an Engagement Manager with McKinsey & Company and Audit Manager with Coopers & Lybrand, now PricewaterhouseCoopers. Laura was a Board Member of Shockwave Medical, Inc. (Nasdaq: SWAV), where she served as Audit Committee Chair and Compensation Committee Member, prior to its acquisition by Johnson & Johnson. She received a B.B.A. from the University of Wisconsin and a M.B.A. from Stanford University. She is a Certified Public Accountant (inactive) in the State of California.

David Lewis

Managing Partner, Gilmartin Capital

David Lewis is the Managing Partner of Gilmartin Capital, a firm he founded in 2021. For the previous 15 years, David was the Head of Medical Device Equity Research at Morgan Stanley, where he covered more than $1.5 trillion in market capitalization and evaluated over 150 M&A and IPO events. During his tenure at Morgan Stanley, David was the top ranked US Equity analyst in Medical Supplies & Devices. Before his time at Morgan Stanley, David was a Partner at Thomas Weisel Partners. David is a key thought leader in the sector, with decades of experience advising medical device companies and boards on strategic and financial direction. David graduated from the University of Pennsylvania with honors and a focus on pre-medical studies.

Steve Anheier

Chief Financial Officer

Steve is Chief Financial Officer at Galvanize. He brings a proven history of driving growth in revenue and profitability. Most recently, Steve was CFO of Vocera Communications, a publicly traded healthcare IT company focused on clinical communication and collaboration, which was acquired by Stryker Corporation for $3.1 billion. Steve was internally promoted into the CFO position at Vocera from his role as Vice President of Finance & Accounting. Prior to Vocera, Steve served in various roles of increasing responsibility for Accuray Incorporated in Strategic Finance and Investor Relations. He started his career at KPMG where he received his CPA and holds a bachelor’s degree in accounting from California Polytechnic State University San Luis Obispo.

Gabe McHugh

Chief Commercial Officer, Galvanize

Gabe is the Chief Commercial Officer of Galvanize. He is an accomplished executive leader with nearly 25 years of success in the MedTech industry. Before joining Galvanize, he served as Executive Vice President and Global Division Head at Olympus, leading the $2.2B Surgical & Interventional Solutions Division and overseeing more than 8,000 employees worldwide. He also held multiple senior leadership roles at Medtronic, Covidien, and Cardinal Health, consistently delivering strong financial performance, market-shaping innovation, and high-performing teams. Known for his strategic clarity, and commercial acumen, he brings deep expertise in scaling businesses, developing markets, and building cultures of accountability and growth. He earned an MBA from Babson College and holds a BS from Tennessee State University.

Seth Harrison, MD

Founder and Managing Partner, ATP

Seth Harrison is founder and managing partner of ATP (Apple Tree Partners), a leading life sciences venture capital firm. Seth began investing in life sciences in 1991 as a venture partner at Sevin Rosen Funds and went on to be a general partner at Oak Investment Partners before starting ATP in 1999. Some of his earlier investments include Aileron Therapeutics, Akero Therapeutics, ArQule, Chinook Therapeutics, Coelacanth, Corvidia Therapeutics, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare, Informed Access, SGX Pharmaceuticals, Stoke Therapeutics, Syntimmune, Tendyne, Ultracision, and ViroPharma. Seth currently serves on the boards of Akero Therapeutics and Stoke Therapeutics as well as the boards of the 15 portfolio companies created within ATP’s current fund to date. From 2002 to 2010, he was a member of the board of the International Partnership for Microbicides, a nonprofit product development partnership focused on women’s health and HIV prevention. Seth received an AB from Princeton University and an MD and MBA both from Columbia University, and completed a surgery internship at the Presbyterian Hospital in the City of New York.

Antoine Papiernik

Chairman & Managing Partner, Sofinnova Partners

Antoine Papiernik is Chairman and Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine actively invests through Sofinnova’s Capital Strategy, the firm’s flagship investment strategy. Over his career, he has been an initial investor and active board member in a number of publicly listed companies including: Actelion (ultimately sold to J&J), ProQR, NovusPharma (sold to CTI), Movetis (sold to Shire), and Shockwave Medical (sold to Johnson and Johnson). Trade sale success stories of private companies include CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis), Ethical Oncology Science (EOS, sold to Clovis Oncology) and Recor Medical (sold to Otsuka). He has also invested in and is a board member of private companies Reflexion Medical, Tissium, Pi-Cardia, SafeHeal, Noema Pharma, May Health, Highlife and Galvanize. Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. He has been selected twice for the Forbes Midas List, an annual ranking recognizing the world’s top venture capital investors. Antoine is one of the few European and life science investors to have appeared on the prestigious list.

Doug Godshall

Chairman and CEO, Galvanize

Doug Godshall was appointed Chief Executive Officer and Chairman of Galvanize in 2025. He served in his prior role as President and CEO of Shockwave Medical until its sale to Johnson & Johnson in 2024 for $13.1B. He is also the former CEO and Director of HeartWare, which was acquired by Medtronic in 2016 for $1.1B. Prior to HeartWare, Doug held executive and leadership positions at Boston Scientific. Doug also serves on the Board of Saluda Medical and is Chairman of the Medical Device Manufacturers of America (MDMA). He earned an MBA from Northeastern University and a BA in Economics from Lafayette College.

Steve Ricottone

Vice President, Global Market Development
Steve is vice president of Global Market Development for the airway/COPD division of Galvanize Therapeutics. In this role, he leads commercial development activities for RheOx globally. Steve is a healthcare executive with more than 15 years of successful healthcare management experience in sales, marketing, and market development, with a focus on developing markets for breakthrough technologies internationally. Steve joined Galvanize Therapeutics from Pulmonx, a global leader in interventional pulmonology that he joined at a very early stage and left post IPO (NASDAQ; LUNG) and where he was vice president of Marketing and Market Development. Previously, Steve held various sales and marketing management roles at Baxter, Zimmer, and Bayer. Steve holds a bachelor’s degree in Physiotherapy from the University of Brussels (Belgium) and a Master of Business Administration (MBA) from the Open University, Milton Keynes (UK).

Michael Iversen

Vice President, Business Development and Commercial Strategy

Michael is Vice President of Business Development and Commercial Strategy. He brings to Galvanize more than 20 years of commercial experience in the Electrophysiology market. He most recently served as Chief Commercial Officer at Acutus Medical and previously worked in various leadership positions at Biotronik, Boston Scientific and Guidant. He holds an MBA from the University of Michigan and a bachelor’s degree in Economics from Copenhagen Business School.

Bill Green

Senior Vice President, Sales and Marketing

Bill serves as senior vice president of Sales and Marketing for Galvanize. Bill has been a part of the Thoracic Oncology and Interventional Oncology space since 2004. He has led early commercial teams at medical device startups, such as superDimension (acquired by Covidien/Medtronic in 2012), NeuWave Medical (acquired by Johnson & Johnson in 2015), and most recently at Auris Health, where he was the vice president of Sales. Auris was acquired by Johnson & Johnson for $3.4 billion in 2019, one of the largest pre-IPO medical device company acquisitions to date. Bill has a bachelor’s degree in Business Finance from Duquesne University.

William S. Krimksy, MD, FCCP, DAABIP

Chief Medical Officer

William Krimsky is Chief Medical Officer of Galvanize Therapeutics®. Bill has been a pioneer in the Interventional Pulmonology space for more than 20 years, carving an innovative pathway for the treatment of lung diseases. In 2015, he and Jonathan Waldstreicher co-founded Galvanize Therapeutics and co-invented the Aliya® and RheOx® technologies, continuing his focus on therapeutic intervention in the pulmonary and oncology fields. Bill earned his medical degree at the University of Pittsburgh School of Medicine and completed an internship at Mercy Hospital and a residency at Johns Hopkins University/Sinai Hospital. Following that, he was a fellow in pulmonary and critical care medicine at Dartmouth-Hitchcock Medical Center and a visiting fellow in Interventional Pulmonology at the Hospital of the University of Pennsylvania. He is the author of multiple publications.

James Stambaugh

Senior Vice President, Clinical Affairs
James is senior vice president of Clinical Affairs for Galvanize. He has over 25 years of experience in medical device and pharmaceutical development, from early-stage start-ups to large, established corporations, and has been responsible for over 35 clinical trials from FIH to pivotal phase III. Prior to joining Galvanize, James was senior vice president of Clinical Affairs at Intersect ENT, where he played a central role in taking the company from inception and concept stage in 2006, through several rounds of VC financing, to an IPO in 2014. Prior to that, James served as director, of Clinical Operations for Guidant’s Vascular Intervention division (acquired by Abbott in 2006), responsible for conduct of clinical studies for embolic protection, coronary stents, and drug-eluting stents. James started his career as an analytical chemist at an ophthalmic pharmaceutical company, InSite Vision. He holds a B.S. in Chemistry from the University of California at Davis.

Deb Sheffield

Chief Regulatory Officer

Deborah Sheffield is Chief Regulatory Officer at Galvanize. She is an experienced professional in the design and development of innovative products, with over 25 years of experience in and understanding of the global regulatory environment in the medical device field. She has successfully obtained US and International medical device approvals for clinical studies and market clearance/approvals for Class I, II and III devices in markets including US, Canada, Australia, South America, India and Europe. Her technology experience encompasses a variety of medical devices platforms, including energy-based therapies (RF, laser, ultrasound, IRE), active implantables, and IVD devices for disease states including neuro, pulmonary, GI and cardiac functions.
Deb has previously held several key leadership positions at companies including Johnson & Johnson and at several start-up companies including Northstar Neuroscience (IPO and subsequently acquired by St. Jude Medical). She holds a BS from Kettering University in Industrial Manufacturing Engineering and a MS from Oakland University in Applied Statistics. She also attended the University of Cincinnati Nursing School with a focus on clinical research.

Kevin Taylor

Chief Operating Officer
Kevin brings to Galvanize nearly three decades of medical device development, operational experience, and industry leadership. His device development experience spans a range of applications, including joint replacement, cardiovascular intervention, ear nose and throat therapies, and therapeutic energy delivery systems. Kevin also has extensive operational experience in pre-commercial and commercial organizations and has held key management positions in companies including Gala Therapeutics, ReCor Medical, Acclarent, and Guidant (now part of Boston Scientific). Kevin earned his mechanical engineering degree at Drexel University and received his MBA degree from the University of Chicago.

Jonathan Waldstreicher, MD

Founder

Jonathan is founder of Galvanize. He has worked in medical devices as an entrepreneur, investor, and clinician. Jon was previously a partner on the MedTech team at ATP, the life sciences venture capital firm where he founded Gala Therapeutics in 2015 and Galaxy Medical in 2020, both of which were merged into Galvanize in 2022. Prior to joining ATP, Jon was a director of Global Surgery R&D at Johnson & Johnson. He started at J&J as an associate director in the Corporate Office of Science & Technology. Before medical school, Jon worked in equity research at Bear Stearns. Jon received a BA from Brandeis University in economics and an MD and MBA from Tufts University School of Medicine. He completed a general surgery internship at Tufts Medical Center in Boston.